Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
Prospective Clinicogenomic Program
Cancer Lung Cancer Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer
Basic Details
Sponsor
Genentech, Inc.
Phase
Phase 4
Study Identifier
NCT04180176, GX41563
Condition
Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Official Title
A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program
Study Summary
The main purpose of this study is to evaluate the feasibility of a scalable, prospective research program for participants with metastatic non-small cell lung cancer (mNSCLC) or extensive-stage small-cell lung cancer (ES-SCLC) planning to start standard-of-care (SOC) systemic anti-cancer treatment. The study will also examine ctDNA status over the course of treatment as a predictor of response to therapy.
Eligibility Criteria
All
≥18 Years
No
Inclusion Criteria
- Documented diagnosis of mNSCLC or ES-SCLC
- Planned initiation of SOC systemic anti-cancer treatment
- Front-Line Immunotherapy Cohort: Received front-line treatment of an immune blockade therapy including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibody on Protocol GX41563
Exclusion Criteria
- Participant actively receiving investigational medicinal product(s) as part of an interventional trial at the time of signing informed consent
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com